Should You Follow Director Buying At National Grid plc, British American Tobacco plc And Advanced Oncotherapy PLC?

Is now the perfect time to invest in National Grid plc (LON:NG), British American Tobacco plc (LON:BATS) and Advanced Oncotherapy PLC (LON:AVO)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Directors have been splashing the cash at National Grid (LSE: NG) (NYSE: NGG.US), British American Tobacco (LSE: BATS) (NYSE: BTI.US) and Advanced Oncotherapy (LSE: AVO). Should you follow their lead and buy shares in these three companies?

National Grid

Jonathan Dawson joined National Grid as a non-executive director in March 2013. During the summer of that year, he and chairman Peter Gershon made a number of sizeable share purchases. However, no National Grid director has made a significant purchase in the two years since — until last week, that is.

With the company’s shares trading not far off their 52-week low, Mr Dawson decided the time was ripe to splash out £85,200 to buy 10,000 shares at 852p for his wife. Mr Dawson is also a non-exec at Jardine Lloyd Thompson, but has bought no further shares in that company since a modest purchase soon after his appointment in 2012.

National Grid is a solid, defensive business; and you can currently buy the shares at around the same price Mr Dawson paid. The stock appears decent value at this level. The trailing price-to-earnings (P/E) ratio of 14.7 is broadly in line with the FTSE 100’s 14.9, but the dividend yield of 5% is well above the index’s 3.6%.

British American Tobacco

Dimitri Panayotopoulos was appointed a non-executive director of British American Tobacco in February this year. By 21 May, he had accumulated 3,300 shares for an average buy price of 3,633p at a total cost of almost £120,000. Mr Panayotopoulos’s timing wasn’t perfect, because the shares have fallen somewhat since — which has been a cue for more directors to buy.

In the past week, finance director Ben Stevens has purchased a modest £18,278 worth of shares at 3,410p; Cristina Dall’Aglio, a person connected with Human Resources boss Giovanni Giordano (an executive just below Main Board level) has bought £68,380 worth of shares at 3,419p; and non-executive director Savio Kwan, who was appointed in January 2014, has chosen to make his first share purchase: 3,000 at 3,405p for a total outlay of over £120,000.

British American Tobacco is another solid, defensive business; and the shares appear reasonably priced at under 3,420p. The P/E of 16.4 is at a bit of a premium to the FTSE 100, but the yield of 4.3% is comfortably higher than that offered by the index.

Advanced Oncotherapy

Moving from tobacco to the treatment of cancer, and from mature megacaps to speculative smaller stocks, we come to Advanced Oncotherapy.

Advanced Oncotherapy’s team is based at CERN in Geneva and is developing a proprietary proton accelerator called Linac Image Guided Hadron Technology for cancer treatment. The shares of this AIM-listed company, which released its annual results on 3 June, have risen 137% since the start of the year to 9.5p, valuing the business at £128m.

On the day of the results, non-executive director Michael Bradfield pulled £147,150 from his wallet to buy 1,500,000 shares at 9.81p. And, before the end of the week, chief executive Sanjeev Pandya and finance director Nicolas Serandour chipped in with modest purchases of about £20,000 each at 9p a share.

What Advanced Oncotherapy is doing is thoroughly admirable from a human welfare perspective, and the directors are evidently confident of the investment case, too. However, it’s difficult to value the business at this stage of its development: the company is currently loss-making, the prospect of a first unit in Harley Street is over a year away, and first patient treatment is not expected until 2017. For me, Advanced Oncotherapy is one to watch for the time being.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK owns shares in JLT. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »